References
Schindler RJ. Study design considersions: conducting global clinical trials in early Alzheimer’s disease. J Nutr Health Aging. 2010 Apr; 14(4):312–341
Cedarbaum JM, Crans G, Grundman M. Seeing with new eyes: finding a path to early intervention trials in Alzheimer’s disease. J Nutr Health Aging. 2010 Apr; 14(4):306–309.
Potter WZ. Dose ranging for trials through biomarkers of drug effects. J Nutr Health Aging. 2010 Apr;14(4):310–311.
Gispen-de Wied CC, Kritsidima M, Elferink AJ. The validity of biomarkers as surrogate endpoints in Alzheimer’s disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLLS). J Nutr Health Aging. 2009 Apr;13(4):376–387.
Douillet P, Orgogozo JM. What we have learned from the Xaliproden Sanofi-aventis trials. J Nutr Health Aging. 2009 Apr;13(4):365–366.
Hendrix SB, Wilcock GK. What we have learned from the Myriad trials. J Nutr Health Aging. 2009 Apr:13(4):362–364. PubMedPMID: 19300881.
Author information
Authors and Affiliations
Additional information
Executive Vice-President for the Campaign to “Prevent Alzheimer’s Disease by 2020”, USA
IPSEN’s Medical Director, France
Rights and permissions
About this article
Cite this article
Andrieu, S., Aboderin, I., Baeyens, J.P. et al. IAGG Workshop: Health promotion program on prevention of late onset dementia. J Nutr Health Aging 15, 562–575 (2011). https://doi.org/10.1007/s12603-011-0142-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-011-0142-1